

**Phytochemical Composition and Pharmacological Potential of *Sophora flavescens*: A Mini Review**

Mostafa M. Atiyah, Sijo Asokan, Smitha Vijayan*

School of Biosciences, Mar Athanasios College for Advanced Studies Tiruvalla (MACFAST), Kerala, India

ARTICLE INFO

Article history:

Received 10 May 2025

Revised 28 July 2025

Accepted 06 August 2025

Published online 01 October 2025

ABSTRACT

Sophora flavescens, commonly known as Kushen, is a perennial shrub extensively used in East Asian traditional medicine to treat various ailments. This review summarises its phytochemical composition and pharmacological activities, focusing on root-derived bioactive compounds. The key constituents, such as quinolizidine alkaloids (matrine and oxymatrine) and flavonoids (kurarinone and kushenol), have been linked to potent antimicrobial, antioxidant, anticancer, anti-inflammatory, hepatoprotective, and neuroprotective effects. A literature search using PubMed, ScienceDirect, and Google Scholar retrieved studies published between 2000 and 2025. The review highlights the major mechanisms of action, including the generation of reactive oxygen species, induction of apoptosis, and modulation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways. Despite these promising properties, challenges such as poor bioavailability, phytochemical variability, and potential toxicity limit its clinical application. Therefore, standardised formulations, integration of omics-based technologies, advanced delivery systems, and rigorous clinical trials are necessary to translate the traditional knowledge of *S. flavescens* into effective evidence-based therapeutics.

Copyright: © 2025 Atiyah *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: *Sophora flavescens*, Phytochemical Composition, Alkaloids, Flavonoids, Pharmacological Properties, Ethnomedicinal Applications

Introduction

Medicinal plants have long played a central role in natural product research and continue to serve as valuable sources for drug discovery and therapeutic development.¹ Among various medicinal plants, *Sophora flavescens* (family Fabaceae), commonly known as Kushen in traditional Chinese medicine (TCM), has attracted increasing scientific interest due to its extensive ethnomedicinal use across East Asia, particularly in China, Korea, and Japan.^{2,3} *S. flavescens* is a perennial shrub, indigenous to these regions and parts of Europe, where it has been traditionally used for centuries to treat various ailments. The dried root and flowering parts of *S. flavescens* serve as the primary medicinal source in traditional formulations, as depicted in Figure 1 to illustrate its key botanical features.^{4,5} Phytochemical investigations have revealed that *S. flavescens* contains diverse bioactive compounds, especially flavonoids such as kurarinone and kushenol, and alkaloids including matrine, oxymatrine, and sophoridine.⁶ These phytoconstituents have been linked to numerous pharmacological benefits, such as antibacterial, antioxidant, anticancer, anti-inflammatory, and neuroprotective effects.⁷ Among its various activities, the antibacterial potential of *S. flavescens* has received considerable attention, primarily due to the synergistic effects of its abundant alkaloids and flavonoids.⁸ Notably, flavonolylated flavonoids such as Sophoraflavanone G and kurarinone are among its most prevalent antibacterial compounds. Both have demonstrated potent antibacterial activity, with minimum inhibitory concentrations (MICs) or fractional inhibitory concentrations (FICs) < 10 mg/mL, often exhibiting synergistic effects with conventional antibiotics.⁹

These compounds are believed to disrupt bacterial membrane permeability, thereby inhibiting growth and damaging cells.¹⁰ In addition to its antibacterial properties, *S. flavescens* has also garnered attention for its hepatoprotective effects. Globally, liver diseases like cirrhosis, hepatic fibrosis, and liver failure represent a major public health burden.¹¹ Reportedly, various constituents, including oxymatrine, matrine, sophoridine, silymarin, glycyrrhizin, and schizandrin B, protect against liver damage.¹² Although most hepatoprotective studies have focused on the alkaloids matrine and sophoridine, there is a growing interest in the protective potential of its flavonoids, especially lavandulyl flavonoids like kushenol C.^{13,14} Thus, the present review aimed to provide a concise and updated overview of the phytochemical composition and pharmacological properties of *S. flavescens*, with a particular focus on its root-derived bioactive compounds. This review emphasises the therapeutic relevance of underexplored flavonoids and the well-known alkaloids, as well as highlights their molecular mechanisms of action, including the modulation of oxidative stress, induction of apoptosis, and regulation of the TLR2/NF- κ B pathway. In addition, it discusses formulation challenges and the potential of nanotechnology-based delivery systems to enhance bioavailability and clinical translation. Herein, a narrative review approach was adopted to facilitate the integration of diverse findings from recent literature and to assess the pharmacological evidence on traditional ethnomedicinal applications. This synthesis aims to support future research and promote the development of *S. flavescens* as a potential therapeutic agent.

Materials and Methods

This narrative literature review followed a systematic search strategy to compile and evaluate peer-reviewed publications related to the phytochemical and pharmacological properties of *S. flavescens*.¹⁵ A comprehensive literature search was performed across PubMed, ScienceDirect and Google Scholar using combinations of keywords such as '*Sophora flavescens*', 'phytochemistry', 'alkaloids', 'flavonoids', 'pharmacological activity' and 'nanodelivery systems'. Articles published in English between 2000 and 2025 were considered. The inclusion criteria encompassed *in vitro*, *in vivo*, or mechanistic studies that specifically addressed the phytochemical constituents or

*Corresponding author. Email: smitha@macfast.org

Tel: +918156840849

Citation: Atiyah MM, Asokan S, Vijayan S. Phytochemical Composition and Pharmacological Potential of *Sophora flavescens*: A Mini Review. Trop J Nat Prod Res. 2025; 9(9) 4084 – 4093 <https://doi.org/10.26538/tjnpr/v9i9.2>

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

therapeutic applications of *S. flavescens*. Non-English language papers, reviews without experimental validation, and conference abstracts were excluded. Titles and abstracts were screened for relevance, and selected articles were assessed in full. This review strategy enabled the synthesis of recent evidence, highlighting the pharmacological significance and translational potential of *S. flavescens* in modern therapeutic research.




Figure 1: Morphological features of *S. flavescens*. (A) flowering plant of *S. flavescens*, (B) dried root slices of *S. flavescens*.

Results and Discussion

Phytochemical Composition of *S. flavescens* Root

The phytochemical screening of *S. flavescens* root identified many bioactive constituents, including alkaloids, flavonoids, saponins, terpenoids, polysaccharides, and glycosides, while tannins were notably absent (Table 1). These compounds are generally categorised into four major pharmacologically active classes, alkaloids, flavonoids, saponins, and polysaccharides, each contributing significantly to the plant's therapeutic potential.⁴ Quinolizidine alkaloids, particularly matrine and its N-oxide derivative, oxymatrine, are the most abundant constituents, responsible for the root's characteristic bitterness, and have been extensively documented for their antiviral, anticancer, and anti-inflammatory properties.¹⁶ Flavonoids, such as kurarinone, sophoraflavanone G, and maackiain, are major contributors to the antioxidant and anti-inflammatory effects of *S. flavescens*. Typically, these phenolic compounds are extracted using ethyl acetate or methanol and are characterised by hydroxyl and methoxy substitutions on the flavanone backbone, influencing their polarity and biological activity.¹⁷ Triterpenoid saponins, including soyasaponin I and kaikasaponin III, also possess immunomodulatory and haemolytic effects. Due to their amphiphilic characteristic, these saponins interact with cellular membranes, potentially enhancing the absorption and bioavailability of co-administered compounds.¹⁸ Notably, phytochemical content may vary due to environmental and cultivation factors, which should be considered in pharmacological evaluations.¹⁹ These findings are consistent with previous reports on other *Sophora* species but highlight the unique flavonoid profile of *S. flavescens*, particularly its lavandulyl-type flavonoids, which are relatively uncommon in related genera.

Pharmacological Activities of *S. flavescens* Root

The pharmacological effects of *S. flavescens* root are primarily attributed to its abundant alkaloids and flavonoids. These bioactive compounds exhibit a wide range of therapeutic activities, including antimicrobial, antioxidant, anticancer, anti-inflammatory, hepatoprotective, and neuroprotective effects, as demonstrated by both *in vitro* and *in vivo* studies (Table 2 and Figure 2).




Figure 2: Summary of major pharmacological activities of *S. flavescens* root and its bioactive constituents

Mechanisms of Action

The pharmacological effects of *S. flavescens* root are mediated through multiple molecular pathways, including the generation of reactive oxygen species (ROS), the induction of apoptosis, and the inhibition of biofilm formation. Root extracts have been shown to induce ROS in microbial pathogens and cancer cells, leading to oxidative damage and cellular apoptosis.⁶⁴ Recent findings also confirm its antifungal activity via CYP51 enzyme inhibition and ROS-mediated fungal cell damage.⁶⁸ Both flavonoids and alkaloids modulate redox-sensitive pathways⁶⁹ and also regulate Bcl-2, Bax, and caspase proteins.⁷⁰ Matrine and oxymatrine increase the mitochondrial membrane permeability, facilitating cytochrome c release and caspase activation.⁷¹ *S. flavescens* disrupts bacterial quorum-sensing, inhibiting biofilm formation and microbial resistance.⁷² Kushenol C and D suppress the TLR2/NF- κ B inflammatory pathway.¹² These multifaceted mechanisms, including ROS generation, apoptosis induction, anti-inflammatory signalling, and quorum-sensing inhibition, are summarised in Figure 3.












Figure 3: Mechanistic pathways of *S. flavescens* root extract

Table 1: Phytochemical screening of *S. flavescens* root

S/N	Phytochemical compounds	Structure	References
1	Oxymatrine		4, 12, 16
2	Sophoridine		13, 20
3	Matrine		16, 21, 22
4	Trifolirhizin		23, 24
5	Isokurarinone		6, 25
6	Kushenol C		14, 12, 26
7	Sophoraflavanone G		8, 27

8


Kurarinone



12,27

9


Kushenol D



14,28

10


Sophocarpidine



14,29

11


3-O-Methylcoumestrol



30

12


Kuraridin



31,32

13


Kaur-16-en-19-ol



33

14


Ginkgetin



34,35

15


Kanzonol K



36

16


Oleuropein



37

17


Neocarthamin



38

18


Kurarinol



39

19


Rheidin A



40

20


Kanzonol G



41

21


Orientalone



42

22

Sophoranone



43










23	Kurarinol		39
	Kushenol F		44
24	Kushenol E		45
25	Sophoraflavanone A		46
26	Kuraridinol		47
27	Kushenin		48
28	Sophoricoside		49
29	Formononetin		50
30	Biochanin A		51

Table 2: Pharmacological activities of major bioactive compounds from *S. flavescens* root

S/N	Pharmacological Activity	Bioactive Compounds	Mechanism of Action	Model/Assay	References
1	Antimicrobial	Sophoraflavanone G, matrine, oxymatrine	Membrane disruption, ROS generation, DNA gyrase inhibition	<i>In vitro</i> (MRSA, <i>E. coli</i>)	52,53,54,55
2	Antioxidant	Kurarinone, kushenol C, kuraridin, isoxanthohumol	DPPH/ABTS scavenging, upregulation of antioxidant enzymes	<i>In vitro</i> antioxidant assays	56,57,58,59
3	Anticancer	Matrine, oxymatrine, trifolirhizin, kurarinone, sophoranone	Apoptosis induction, NF-κB and PI3K/Akt/mTOR inhibition, mitochondrial disruption	A549, A2780, HCT116, colorectal models	14, 20, 60, 61,62,63
4	Anti-inflammatory	Kushenol C, kurarinone	TLR2/NF-κB inhibition, cytokine suppression (TNF-α, IL-6, COX-2)	LPS-activated macrophages	12, 64, 65
5	Hepatoprotective	Matrine, sophoridine	Antioxidant effects, stabilization of liver enzymes	CCl ₄ -induced hepatotoxicity	11, 12, 26
6	Neuroprotective	Kurarinone, matrine	Amyloid-β inhibition, ROS suppression, anti-inflammatory signaling	Neuronal cells, AD models	21, 66, 67

Abbreviations: ROS, reactive oxygen species; DPPH, 2,2-diphenyl-1-picrylhydrazyl; ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K/Akt/mTOR, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin; TLR2, toll-like receptor 2; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; COX-2, cyclooxygenase-2

Challenges in Drug Development and Clinical Applications

Despite the promising pharmacological effects, the clinical translation of *S. flavescens* is limited due to the poor bioavailability of matrine and oxymatrine, which have short half-lives (1.5–4.7 h).⁷³ A previous study has reported hepatotoxicity, neurotoxicity, and environmental risks.⁷⁴ Herb-drug interactions may reduce the efficacy of co-administered agents such as indinavir via cytochrome P450 family 3 subfamily A (CYP3A) and P-glycoprotein induction.⁷⁵ Phytochemical variability across sources complicates standardisation, with matrine levels differing by up to 40%.⁷⁶ Owing primarily to preclinical evidence, rigorous clinical trials are essential. Nanocarrier systems and standardised formulations are critical to ensure therapeutic translation. Addressing these challenges requires future research to focus on innovative delivery systems, omics-based standardisation, and well-designed clinical trials.

Conclusion

S. flavescens root possesses significant pharmacological potential, supported by a diverse profile of bioactive compounds, particularly alkaloids and flavonoids. These constituents contribute to various therapeutic activities, including antimicrobial, antioxidant, anticancer, anti-inflammatory, hepatoprotective, and neuroprotective effects, through mechanisms such as oxidative stress modulation, apoptosis induction, and inflammatory pathway regulation. However, limitations such as poor bioavailability, toxicity concerns, and insufficient clinical validation currently hinder its clinical application. Thus, future research should focus on developing standardised formulations, improving delivery through nanotechnology-based systems, and conducting rigorous clinical trials. Integrating omics technologies and sustainable sourcing approaches will further support the safe and effective translation of *S. flavescens* into modern therapeutic use.

Conflict of Interest

The author's declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgements

The authors gratefully acknowledge the support provided by the School of Biosciences, Mar Athanasios College for Advanced Studies Tiruvalla (MACFAST), affiliated with Mahatma Gandhi University, Kottayam, and the Indian Council for Cultural Relations (ICCR), New Delhi, India.

References

- Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. *Curr Top Med Chem*. 2012; 12:1356 - 1362. Doi: [10.2174/156802612801319034](https://doi.org/10.2174/156802612801319034)
- Wang X, Sun H, Zhang A, Sun W, Wang P, Wang Z. Potential role of metabolomics approaches in the area of traditional Chinese medicine: as pillars of the bridge between Chinese and Western medicine. *J Pharm Biomed Anal*. 2011; 55:859-868. Doi: [10.1016/j.jpba.2011.01.042](https://doi.org/10.1016/j.jpba.2011.01.042)
- Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, Chan K. Syndrome differentiation in modern research of traditional Chinese medicine. *J Ethnopharmacol*. 2012; 140:634-642. Doi: [10.1016/j.jep.2012.01.033](https://doi.org/10.1016/j.jep.2012.01.033)
- He X, Fang J, Huang L, Wang J, Huang X. *Sophora flavescens* Ait.: Traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. *J Ethnopharmacol*. 2015; 172:10-29. Doi: [10.1016/j.jep.2015.06.010](https://doi.org/10.1016/j.jep.2015.06.010)
- Falodun A, Siraj R, Choudhary MI. GC-MS insecticidal leaf essential oil of *Pyrenacantha staudtii* Hutch and Dalz (Icacinaeae). *Trop J Pharm Res*. 2009; 8(2):139–143.

6. Jiaqi ZH, Hong LI, Rui QI, Choi HY, Xinzhou YA. Ethnomedicinal uses, phytochemistry and bioactivities of *Sophora flavescens* Ait.: A review. J Holist Integr Pharm. 2021; 2:163-195.
7. Li P, Chai WC, Wang ZY, Tang KJ, Chen JY, Venter H, Semple SJ, Xiang L. Bioactivity-guided isolation of compounds from *Sophora flavescens* with antibacterial activity against *Acinetobacter baumannii*. Nat Prod Res. 2022; 36:4334-4342. Doi: [10.1080/14786419.2021.1983570](https://doi.org/10.1080/14786419.2021.1983570)
8. Sun ZL, Sun SC, He JM, Lan JE, Gibbons S, Mu Q. Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant *Staphylococcus aureus*. Int J Antimicrob Agents. 2020; 56:106098. DOI: [10.1016/j.ijantimicag.2020.106098](https://doi.org/10.1016/j.ijantimicag.2020.106098)
9. Tsuchiya H, Inuma M. Reduction of membrane fluidity by antibacterial sophoraflavanone G isolated from *Sophora exigua*. Phytomedicine. 2000; 7:161-165. Doi: [10.1016/S0944-7113\(00\)80089-6](https://doi.org/10.1016/S0944-7113(00)80089-6)
10. Sharma B, John S. Hepatic cirrhosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
11. Mou Y, Liao W, Li Y, Wan L, Liu J, Luo X, Shen H, Sun Q, Wang J, Tang J, Wang Z. Glycyrrhizin and the related preparations: an inspiring resource for the treatment of liver diseases. Am J Chin Med. 2024; 52:315-354. Doi: [10.1142/S0192415X24500149](https://doi.org/10.1142/S0192415X24500149)
12. Lin Y, Chen XJ, Li JJ, He L, Yang YR, Zhong F, He MH, Shen YT, Tu B, Zhang X, Zeng Z. A novel type lavandulyl flavonoid from *Sophora flavescens* as potential anti-hepatic injury agent that inhibits TLR2/NF- κ B signaling pathway. J Ethnopharmacol. 2023; 307:116163. DOI: [10.1016/j.jep.2023.116163](https://doi.org/10.1016/j.jep.2023.116163)
13. Roy A, Khan A, Ahmad I, Alghamdi S, Rajab BS, Babalghith AO, Alshahrani MY, Islam S, Islam MR. Flavonoids: a bioactive compound from medicinal plants and its therapeutic applications. Biomed Res Int. 2022; 2022:5445291. Doi: [10.1155/2022/5445291](https://doi.org/10.1155/2022/5445291)
14. Abd-Alla HI, Souguir D, Radwan MO. Genus *Sophora*: a comprehensive review on secondary chemical metabolites and their biological aspects from past achievements to future perspectives. Arch Pharm Res. 2021;44:903-986. Doi: [10.1007/s12272-021-01354-2](https://doi.org/10.1007/s12272-021-01354-2)
15. Ferrari R. Writing narrative style literature reviews. Med Writ. 2015; 24:230-235.
16. Xu Y, Wang X, Sa K, Li H, Chen L. Alkaloids from the roots of *Sophora flavescens* and their anti-tumor activity. Fitoterapia. 2023; 171:105685. Doi: [10.1016/j.fitote.2023.105685](https://doi.org/10.1016/j.fitote.2023.105685)
17. Lin CF, Lin MH, Hung CF, Alshetali A, Tsai YF, Zhong CL, Fang JY. The anti-inflammatory activity of flavonoids and alkaloids from *Sophora flavescens* alleviates psoriasiform lesions: prenylation and methoxylation beneficially enhance bioactivity and skin targeting. Phytother Res. 2024; 38:1951-1970. Doi: [10.1002/ptr.8140](https://doi.org/10.1002/ptr.8140)
18. Timilsena YP, Phosanam A, Stockmann R. Perspectives on saponins: food functionality and applications. Int J Mol Sci. 2023; 24:13538. Doi: [10.3390/ijms241713538](https://doi.org/10.3390/ijms241713538)
19. Rawat P, Dasila K, Singh M, Kumar R, Bhatt A. Influence of environmental factors on phytochemical compositions and antioxidant activity of *Juniperus communis* L. Discov Environ. 2025; 3:11.
20. Tang Q, Liu Y, Peng X, Wang B, Luan F, Zeng N. Research progress in the pharmacological activities, toxicities, and pharmacokinetics of sophoridine and its derivatives. Drug Des Devel Ther. 2022; 16: 191-212. Doi: [10.2147/DDDT.S339555](https://doi.org/10.2147/DDDT.S339555)
21. Esmeeta A, Adhikary S, Dharshnaa V, Swarnamughi P, Maqsummiya ZU, Banerjee A, Pathak S, Duttaroy AK. Plant-derived bioactive compounds in colon cancer treatment: an updated review. Biomed Pharmacother. 2022; 153:113384. Doi: [10.1016/j.biopha.2022.113384](https://doi.org/10.1016/j.biopha.2022.113384)
22. Liu J, Li T, Zhong G, Pan Y, Gao M, Su S, Liang Y, Ma C, Liu Y, Wang Q, Shi Q. Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological properties. Biomed Pharmacother. 2023; 166:115406. Doi: [10.1016/j.biopha.2023.115406](https://doi.org/10.1016/j.biopha.2023.115406)
23. Huang XB, Yuan LW, Shao J, Yang Y, Liu Y, Lu JJ, Chen L. Cytotoxic effects of flavonoids from root of *Sophora flavescens* in cancer cells. Nat Prod Res. 2021; 35(22):4317-4322. Doi: [10.1080/14786419.2020.1712382](https://doi.org/10.1080/14786419.2020.1712382)
24. Cho BO, Che DN, Kim JS, Kim JH, Shin JY, Kang HJ, Jang SI. In vitro anti-inflammatory and anti-oxidative stress activities of kushenol C isolated from the roots of *Sophora flavescens*. Molecules. 2020; 25(8):1768. Doi: [10.3390/molecules25081768](https://doi.org/10.3390/molecules25081768)
25. Weng Z, Zeng F, Wang M, Guo S, Tang Z, Itagaki K, Lin Y, Shen X, Cao Y, Duan JA, Wang F. Antimicrobial activities of lavandulylated flavonoids in *Sophora flavescens* against methicillin-resistant *Staphylococcus aureus* via membrane disruption. J Adv Res. 2024; 57:197-212. Doi: [10.1016/j.jare.2023.04.017](https://doi.org/10.1016/j.jare.2023.04.017)
26. Meng X, Tang GY, Liu PH, Zhao CJ, Liu Q, Li HB. Antioxidant activity and hepatoprotective effect of 10 medicinal herbs on CCl₄-induced liver injury in mice. World J Gastroenterol. 2020; 26(37):5629-5645. Doi: [10.3748/wjg.v26.i37.5629](https://doi.org/10.3748/wjg.v26.i37.5629)
27. Wang F, Shin JY, Kang ES, Kim JH, Jang SI, Cho BO. Kushenol C from *Sophora flavescens* protects against UVB-induced skin damage in mice through suppression of inflammation and oxidative stress. Heliyon. 2023; 9(12):e20459. Doi: [10.1016/j.heliyon.2023.e22804](https://doi.org/10.1016/j.heliyon.2023.e22804)
28. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-392. Doi: [10.1128/mmb.61.3.377-392.1997](https://doi.org/10.1128/mmb.61.3.377-392.1997)
29. Wang M, Liu X, Chen T, Cheng X, Xiao H, Meng X, Jiang Y. Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways. Front Oncol. 2022; 12:956793. Doi: [10.3389/fonc.2022.956793](https://doi.org/10.3389/fonc.2022.956793)
30. National Center for Biotechnology Information (NCBI). 3-O-Methylcoumestrol, PubChem Compound Summary. [Online]. 2025 [cited 2025 Jul 1]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/3-O-Methylcoumestrol>
31. Jeon S, Youn K, Jun M. Discovery of kuraridin as a potential natural anti-melanogenic agent: focusing on specific target genes and multidirectional signaling pathways. Int J Mol Sci. 2024; 25(20):11227. Doi: [10.3390/ijms252011227](https://doi.org/10.3390/ijms252011227)
32. National Center for Biotechnology Information (NCBI). Kuraridin, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Kuraridin>
33. National Center for Biotechnology Information (NCBI). ent-Kaur-16-en-19-ol, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/ent-Kaur-16-en-19-ol>
34. Šamec D, Karalija E, Dahija S, Hassan STS. Biflavonoids: Important contributions to the health benefits of Ginkgo (*Ginkgo biloba* L.). Plants. 2022; 11(10):1381. Doi: [10.3390/plants11101381](https://doi.org/10.3390/plants11101381)
35. National Center for Biotechnology Information (NCBI). Ginkgetin, PubChem Compound Summary. [Online]. 2025 [cited 2025 Jul 6]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Ginkgetin>
36. National Center for Biotechnology Information (NCBI). Kanzonol K, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Kanzonol-K>
37. National Center for Biotechnology Information (NCBI). Oleuropein, PubChem Compound Summary. [Online]. 2025

- [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Oleuropein>
38. National Center for Biotechnology Information (NCBI). Neocarthamin, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Neocarthamin>
 39. National Center for Biotechnology Information (NCBI). Kurarinol, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Kurarinol>
 40. National Center for Biotechnology Information (NCBI). Rheidin A, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Rheidin-A>
 41. National Center for Biotechnology Information (NCBI). Kazonol G, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Kazonol-G>
 42. National Center for Biotechnology Information (NCBI). Orientalone, PubChem Compound Summary. [Online]. 2025 [cited 2025 Apr 30]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Orientalone>
 43. Long GQ, Hu GS, Gao XX, Jia JM, Wang AH. Sophoranone A and B: two new cytotoxic prenylated metabolites and their analogs from the root bark of *Sophora flavescens*. Nat. Prod. Res. 2022; 36(6):1515-1521. Doi: [10.1080/14786419.2021.1894562](https://doi.org/10.1080/14786419.2021.1894562)
 44. Yang X, Cheng J, Yin X, Ao T, He X, Yang Y, Lin Y, Chen Z. Metabolic profiling for unveiling mechanisms of kushenol F against imiquimod-induced psoriasis with UHPLC/MS analysis. Molecules. 2024; 29(11):2410. Doi: [10.3390/molecules29112410](https://doi.org/10.3390/molecules29112410)
 45. Kwon M, Jang M, Kim GH, Oh T, Ryoo IJ, Ryu HW, Oh SR, Kim BY, Jang JH, Ko SK, Ahn JS. Kushenol E inhibits autophagy and impairs lysosomal positioning via VCP/p97 inhibition. Biochem. Pharmacol. 2020; 175:113861. Doi: [10.1016/j.bcp.2020.113861](https://doi.org/10.1016/j.bcp.2020.113861)
 46. Zhu H, Yang YN, Feng ZM, Jiang JS, Zhang PC. Sophoflavanones A and B, two novel prenylated flavanones from the roots of *Sophora flavescens*. Bioorg. Chem. 2018; 79:122-125. Doi: [10.1016/j.bioorg.2018.04.019](https://doi.org/10.1016/j.bioorg.2018.04.019)
 47. Hyun SK, Lee WH, Jeong DM, Kim Y, Choi JS. Inhibitory effects of kurarinol, kuraridinol, and trifolirhizin from *Sophora flavescens* on tyrosinase and melanin synthesis. Biol. Pharm. Bull. 2008; 31(1):154-158. Doi: [10.1248/bpb.31.154](https://doi.org/10.1248/bpb.31.154)
 48. Yang YN, Zhu H, Yuan X, Zhang X, Feng ZM, Jiang JS, Zhang PC. Seven new prenylated flavanones from the roots of *Sophora flavescens* and their anti-proliferative activities. Bioorg. Chem. 2021; 109:104716. Doi: [10.1016/j.bioorg.2021.104716](https://doi.org/10.1016/j.bioorg.2021.104716)
 49. Liu Y, Zhao Y, Guo Q, Wang P, Li P, Du Q, Xu H, Yu Q, Zhao X, Zhang W, An S. Sophoricoside reduces inflammation in type II collagen-induced arthritis by downregulating NLRP3 signaling. Biochem. Biophys. Rep. 2024; 40:101867. Doi: [10.1016/j.bbrep.2024.101867](https://doi.org/10.1016/j.bbrep.2024.101867)
 50. Tay KC, Tan LT, Chan CK, Hong SL, Chan KG, Yap WH, Pusparajah P, Lee LH, Goh BH. Formononetin: a review of its anticancer potentials and mechanisms. Front. Pharmacol. 2019; 10:820. Doi: [10.3389/fphar.2019.00820](https://doi.org/10.3389/fphar.2019.00820)
 51. Raheja S, Girdhar A, Lather V, Pandita D. Biochanin A: a phytoestrogen with therapeutic potential. Trends Food Sci. Technol. 2018; 79:55-66.
 52. Al-Hayanni HS, Alnuaimi MT, AL-Lami RA, Zaboon SM. Antibacterial effect of silver nanoparticles prepared from *Sophora flavescens* root aqueous extracts against multidrug-resistant *Pseudomonas aeruginosa* and *Staphylococcus aureus*. J. Pure Appl. Microbiol. 2022; 16(4):2880-2890.
 53. Cha JD, Moon SE, Kim JY, Jung EK, Lee YS. Antibacterial activity of sophoraflavanone G isolated from the roots of *Sophora flavescens* against methicillin-resistant *Staphylococcus aureus*. Phytother. Res. 2009; 23(9):1326 - 1331. Doi: [10.1002/ptr.2540](https://doi.org/10.1002/ptr.2540)
 54. Gao Y, Sun J, Li W, Deng W, Wang Y, Li X, Yang Z. Sophoraflavanone G: a review of the phytochemistry and pharmacology. Fitoterapia. 2024; 168:106080. Doi: [10.1016/j.fitote.2024.106080](https://doi.org/10.1016/j.fitote.2024.106080)
 55. Kong S, Liu Y, Tang R, Liao Q, Bai D, Lv D, Xu Z, Lin L, Li H. Ultrasound-assisted extraction of prenylated flavonoids from *Sophora flavescens*: optimization, mechanistic characterization, antioxidant and anti-inflammatory activities. Ind. Crops Prod. 2025; 225:120559.
 56. Li J, Lin Y, He L, Ou R, Chen T, Zhang X, Li Q, Zeng Z, Long Q. Two new isoprenoid flavonoids from *Sophora flavescens* with antioxidant and cytotoxic activities. Molecules. 2021; 26(23):7228. Doi: [10.3390/molecules26237228](https://doi.org/10.3390/molecules26237228)
 57. Piao XL, Piao XS, Kim SW, Park JH, Kim HY, Cai SQ. Identification and characterization of antioxidants from *Sophora flavescens*. Biol. Pharm. Bull. 2006; 29(9):1911-1915. Doi: [10.1248/bpb.29.1911](https://doi.org/10.1248/bpb.29.1911)
 58. Okolie NP, Falodun A, Davids O. Evaluation of the antioxidant activity of root extract of pepper fruit (*Dennetia tripetala*) and its potential for the inhibition of lipid peroxidation. Afr. J. Tradit. Complement. Altern. Med. 2014; 11(3):221-227. Doi: [10.4314/ajtcam.v11i3.31](https://doi.org/10.4314/ajtcam.v11i3.31)
 59. Sun M, Cao H, Sun L, Dong S, Bian Y, Han J, Zhang L, Ren S, Hu Y, Liu C, Xu L. Antitumor activities of kushen: literature review. Evid. Based Complement. Alternat. Med. 2012; 2012:373219. Doi: [10.1155/2012/373219](https://doi.org/10.1155/2012/373219)
 60. Chen MH, Gu YY, Zhang AL, Sze DM, Mo SL, May BH. Biological effects and mechanisms of matrine and other constituents of *Sophora flavescens* in colorectal cancer. Pharmacol. Res. 2021; 171:105778. Doi: [10.1016/j.phrs.2021.105778](https://doi.org/10.1016/j.phrs.2021.105778)
 61. Yang YF, Liu TT, Li GX, Chen XQ, Li RT, Zhang ZJ. Flavonoids from the roots of *Sophora flavescens* and their potential anti-inflammatory and antiproliferative activities. Molecules. 2023; 28(5):2048. Doi: [10.3390/molecules28052048](https://doi.org/10.3390/molecules28052048)
 62. Vijayalakshmi M, Meganathan S, Surendhar SK, Umamaheswari A, Lakshmana Prabu S. Exploring the systematic anticancer mechanism in selected medicinal plants: a review. Oncol. Adv. 2024; 2(3):141-147.
 63. Li Y, Zhang T, Chen GY. Flavonoids and colorectal cancer prevention. Antioxidants. 2018; 7(12):187. Doi: [10.3390/antiox7120187](https://doi.org/10.3390/antiox7120187)
 64. Oh J, Kim SA, Kwon KW, Choi SR, Lee CH, Hossain MA, Kim ES, Kim C, Lee BH, Lee S, Kim JH. *Sophora flavescens* Aiton methanol extract exerts anti-inflammatory effects via reduction of Src kinase phosphorylation. J. Ethnopharmacol. 2023; 305:116015. Doi: [10.1016/j.jep.2022.116015](https://doi.org/10.1016/j.jep.2022.116015)
 65. Ma H, Huang Q, Qu W, Li L, Wang M, Li S, Chu F. *In vivo* and *in vitro* anti-inflammatory effects of *Sophora flavescens* residues. J. Ethnopharmacol. 2018; 224:497-503. Doi: [10.1016/j.jep.2018.06.019](https://doi.org/10.1016/j.jep.2018.06.019)
 66. Chen SY, Gao Y, Sun JY, Meng XL, Yang D, Fan LH, Xiang L, Wang P. Traditional Chinese medicine: role in reducing β -amyloid, apoptosis, autophagy, neuroinflammation, oxidative stress, and mitochondrial dysfunction of Alzheimer's disease. Front. Pharmacol. 2020; 11:497. Doi: [10.3389/fphar.2020.00497](https://doi.org/10.3389/fphar.2020.00497)
 67. Hole KL, Williams RJ. Flavonoids as an intervention for Alzheimer's disease: progress and hurdles towards defining a mechanism of action. Brain Plast. 2020; 6(2):167-192. Doi: [10.3233/BPL-200098](https://doi.org/10.3233/BPL-200098)
 68. Atiyah MM, Merlin T, Vijayan S. Antifungal potential of *Sophora flavescens* root extract: HR-LCMS analysis and molecular docking of bioactive compounds against nosocomial fungal pathogens. J Pure Appl Microbiol. 2025; 19(3):1-14. Doi: [10.22207/JPAM.19.3.10](https://doi.org/10.22207/JPAM.19.3.10)

69. Bouyahya A, Bakrim S, Aboulaghras S, El Kadri K, Aanniz T, Khalid A, Abdalla AN, Abdallah AA, Ardianto C, Ming LC, El Omari N. Bioactive compounds from nature: antioxidants targeting cellular transformation in response to epigenetic perturbations induced by oxidative stress. *Biomed. Pharmacother.* 2024; 174:116432. Doi: [10.1016/j.biopha.2024.116432](https://doi.org/10.1016/j.biopha.2024.116432)
70. Iksen, Witayateeraporn W, Hardianti B, Pongrakhananon V. Comprehensive review of Bcl-2 family proteins in cancer apoptosis: therapeutic strategies and promising updates of natural bioactive compounds and small molecules. *Phytother. Res.* 2024; 38(5):2249-2275. Doi: [10.1002/ptr.8157](https://doi.org/10.1002/ptr.8157)
71. Jiang H, Hou C, Zhang S, Xie H, Zhou W, Jin Q, Cheng X, Qian R, Zhang X. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. *Eur. J. Pharmacol.* 2007; 559(2-3):98-108. Doi: [10.1016/j.ejphar.2006.12.017](https://doi.org/10.1016/j.ejphar.2006.12.017)
72. Mitra A. Combatting biofilm-mediated infections in clinical settings by targeting quorum sensing. *Cell Surf.* 2024; 8:100133. DOI: [10.1016/j.tcsu.2024.100133](https://doi.org/10.1016/j.tcsu.2024.100133)
73. Liu M, Jin S, Yan H, Du S. Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine. *Eur. J. Pharm. Sci.* 2017; 104:212-220. Doi: [10.1016/j.ejps.2017.03.048](https://doi.org/10.1016/j.ejps.2017.03.048)
74. Yang N, Guo J, Zhang J, Gao S, Xiang Q, Wen J, Huang Y, Rao C, Chen Y. A toxicological review of alkaloids. *Drug Chem. Toxicol.* 2024; 47(6):1267-1281. Doi: [10.1080/01480545.2024.2326051](https://doi.org/10.1080/01480545.2024.2326051)
75. Yang JM, Ip SP, Xian Y, Zhao M, Lin ZX, Yeung JH, Chan RC, Lee SS, Che CT. Impact of the herbal medicine *Sophora flavescens* on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. *PLoS One.* 2012; 7(2):e31312. Doi: [10.1371/journal.pone.0031312](https://doi.org/10.1371/journal.pone.0031312)
76. Kumar A, P N, Kumar M, Jose A, Tomer V, Oz E, Proestos C, Zeng M, Elobeid T, K S, Oz F. Major phytochemicals: recent advances in health benefits and extraction method. *Molecules.* 2023; 28(2):887. Doi: [10.3390/molecules28020887](https://doi.org/10.3390/molecules28020887)